In today’s recent session, 0.44 million shares of the Aquestive Therapeutics Inc (NASDAQ:AQST) have been traded, and its beta is 2.66. Most recently the company’s share price was $4.53, and it changed around $0.09 or 2.14% from the last close, which brings the market valuation of the company to $401.73M. AQST at last check was trading at a discount to its 52-week high of $6.23, offering almost -37.53% off that amount. The share price’s 52-week low was $1.61, which indicates that the recent value has risen by an impressive 64.46% since then. We note from Aquestive Therapeutics Inc’s average daily trading volume that its 10-day average is 1.95 million shares, with the 3-month average coming to 1.34 million.
Aquestive Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended AQST as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Aquestive Therapeutics Inc is expected to report earnings per share of -0.13 for the current quarter.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Instantly AQST has been showing a green trend so far today with a performance of 2.14% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.25 on recent trading dayincreased the stock’s daily price by 13.71%. The company’s shares are currently up 124.50% year-to-date, but still down -10.55% over the last five days. On the other hand, Aquestive Therapeutics Inc (NASDAQ:AQST) is -9.84% down in the 30-day period. We can see from the shorts that 10.14 million shares have been sold at a short interest cover period of 7.97 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 54.7% from its current value. Analyst projections state that AQST is forecast to be at a low of $9 and a high of $12.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Aquestive Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 42.16 percent over the past six months and at a -246.15% annual growth rate that is well below the industry average of 15.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -44.49% in revenue this quarter, and will report an increase of 11.67% in the next quarter. The year-over-year growth rate is expected to be 13.38%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 13.13M in revenue for the current quarter. 5 analysts expect Aquestive Therapeutics Inc to make 13.08M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 13.21M and 12.05M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -0.60%. Forecasts for the next quarter put sales growth at 8.52%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 46.61%.
AQST Dividends
Aquestive Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-03.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.01% of Aquestive Therapeutics Inc shares, and 52.43% of them are in the hands of institutional investors. The stock currently has a share float of 55.19%. Aquestive Therapeutics Inc stock is held by 149.0 institutions, with BRATTON CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 13.3274% of the shares, which is about 9.81 million shares worth $25.51 million.
VR ADVISER, LLC, with 7.5468% or 5.56 million shares worth $14.44 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
